Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone434-220-0718
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees10
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions
What is Diffusion Pharmaceuticals' stock symbol?
Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."
When did Diffusion Pharmaceuticals' stock split? How did Diffusion Pharmaceuticals' stock split work?
Shares of Diffusion Pharmaceuticals reverse split on the morning of Friday, December 14th 2018. The 1-15 reverse split was announced on Thursday, December 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 13th 2018. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.
How were Diffusion Pharmaceuticals' earnings last quarter?
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) issued its earnings results on Thursday, August, 8th. The company reported ($0.63) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.06. View Diffusion Pharmaceuticals' Earnings History.
When is Diffusion Pharmaceuticals' next earnings date?
What price target have analysts set for DFFN?
1 equities research analysts have issued 1 year price objectives for Diffusion Pharmaceuticals' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Diffusion Pharmaceuticals' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 640.7% from the stock's current price. View Analyst Price Targets for Diffusion Pharmaceuticals.
What is the consensus analysts' recommendation for Diffusion Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diffusion Pharmaceuticals.
Has Diffusion Pharmaceuticals been receiving favorable news coverage?
Media headlines about DFFN stock have been trending negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Diffusion Pharmaceuticals earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Diffusion Pharmaceuticals.
Are investors shorting Diffusion Pharmaceuticals?
Diffusion Pharmaceuticals saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 80,300 shares, a decline of 19.9% from the August 30th total of 100,200 shares. Based on an average daily volume of 65,100 shares, the short-interest ratio is presently 1.2 days. Approximately 1.8% of the company's stock are short sold. View Diffusion Pharmaceuticals' Current Options Chain.
Who are some of Diffusion Pharmaceuticals' key competitors?
Some companies that are related to Diffusion Pharmaceuticals include Aptevo Therapeutics (APVO), Alimera Sciences (ALIM), ContraFect (CFRX), Intec Pharma (NTEC), Ceapro (CRPOF), Acerus Pharmaceuticals (TRLPF), OncoSec Medical (ONCS), Provectus Biopharmaceuticals (PVCT), Sierra Oncology (SRRA), AEterna Zentaris (AEZS), ProPhase Labs (PRPH), Cassava Sciences (SAVA), Aytu Bioscience (AYTU), Seelos Therapeutics (SEEL) and Mateon Therapeutics (MATN).
What other stocks do shareholders of Diffusion Pharmaceuticals own?
Who are Diffusion Pharmaceuticals' key executives?
Diffusion Pharmaceuticals' management team includes the folowing people:
- Mr. David G. Kalergis, Co-Founder, CEO & Chairman (Age 70)
- Dr. John L. Gainer, Co-Founder, Chief Scientific Officer & Director (Age 80)
- Mr. William Karl Hornung, Chief Financial Officer (Age 50)
- Mr. Thomas E. Byrne, Gen. Counsel (Age 62)
- Dr. David Randolph Jones M.D., Sr. Medical Advisor (Age 56)
How do I buy shares of Diffusion Pharmaceuticals?
Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Diffusion Pharmaceuticals' stock price today?
One share of DFFN stock can currently be purchased for approximately $1.35.
How big of a company is Diffusion Pharmaceuticals?
Diffusion Pharmaceuticals has a market capitalization of $6.34 million. The company earns $-18,370,000.00 in net income (profit) each year or ($6.08) on an earnings per share basis. Diffusion Pharmaceuticals employs 10 workers across the globe.View Additional Information About Diffusion Pharmaceuticals.
What is Diffusion Pharmaceuticals' official website?
How can I contact Diffusion Pharmaceuticals?
Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected]
MarketBeat Community Rating for Diffusion Pharmaceuticals (NASDAQ DFFN)
MarketBeat's community ratings are surveys of what our community members think about Diffusion Pharmaceuticals and other stocks. Vote "Outperform" if you believe DFFN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DFFN will underperform the S&P 500 over the long term. You may vote once every thirty days.
